These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Aggressive lipid-lowering therapy: a clinical imperative.
    Author: Pedersen TR.
    Journal: Eur Heart J; 1998 Oct; 19 Suppl M():M15-21. PubMed ID: 9821012.
    Abstract:
    Overwhelming evidence from epidemiological and clinical studies has demonstrated that low density lipoprotein cholesterol (LDL-C) is a key element in the development of atherosclerosis, and that reducing LDL-C levels results in a lower risk of coronary heart disease (CHD). As a result, greater emphasis is being placed on the need for effective cholesterol reduction in individuals at risk of CHD. Early lipid-lowering trials, using fibrates and bile acid sequestrants, achieved only modest reductions in plasma LDL-C, and had a disappointing impact on total mortality. Recent studies using more effective lipid-lowering agents--3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors--demonstrated more substantial reductions in cholesterol and were associated with significant reductions in coronary, and all-cause, mortality. However, the extent of LDL-C reduction achieved often fell short of LDL-C treatment targets recommended in national and international guidelines. Analysis of data from a range of studies suggests that more aggressive lipid-lowering therapy results in a greater reduction in the risk of major coronary events. However, it is not only the final LDL-C level achieved that affects CHD risk, but also the degree of cholesterol lowering that has occurred, such that the lower the level of LDL-C achieved, the greater the benefit in terms of reduced CHD events. Patients that demonstrate the greatest changes in LDL-C levels seem to benefit most from lipid-lowering treatment.
    [Abstract] [Full Text] [Related] [New Search]